CoChat

Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients

Open access
Kasikova, Lenka, Hensler, Michal, Truxova, Iva, Skapa, Petr, Laco, Jan, Belicova, Lucie, Praznovec, Ivan, Vosahlikova, Sarka, Halaska, Michael J., Brtnicky, Tomas, Rob, Lukas, Presl, Jiri, Kostun, Jan, Cremer, Isabelle, Ryska, Ales, Kroemer, Guido, Galluzzi, Lorenzo, Spisek, Radek, Fucikova, Jitka · 2019 · Journal for ImmunoTherapy of Cancer

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Adjuvanticity, which is the ability of neoplastic cells to deliver danger signals, is critical for the host immune system to mount spontaneous and therapy-driven anticancer immune responses. One of such signals, i.e., the exposure of calreticulin (CALR) on the membrane of malignant cells experiencing endoplasmic reticulum (ER) stress, is well known for its role in the activation of immune responses to dying cancer cells. However, the potential impact of CALR on the immune contexture of primary and metastatic high-grade serous carcinomas (HGSCs) and its prognostic value for patients with HGSC remains unclear. METHOD: We harnessed a retrospective cohort of primary (no = 152) and metastatic (no = 74) tumor samples from HGSC patients to investigate the CALR expression in relation with prognosis and function orientation of the tumor microenvironment. IHC data were complemented with transcriptomic and functional studies on second prospective cohort of freshly resected HGSC samples. In silico analysis of publicly available RNA expression data from 302 HGSC samples was used as a confirmatory approach. RESULTS: 1 polarization and cytotoxic activity that enables superior clinical benefits. CONCLUSIONS: Our data indicate that CALR levels in primary and metastatic HGSC samples have robust prognostic value linked to the activation of clinically-relevant innate and adaptive anticancer immune responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0781-z

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Prognostic impact of CALR expression in the primary TME of HGSC patients. a Representative images of CALR immunostaining in CALRLo and CALRHi patients. Scale bar = 100 μm. b CALR expression levels among different pathological disease stages. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. RFS (c) and OS (d) of 152 HGSC patients who did not receive neoadjuvant chemotherapy, upon stratification based on median CALR expression. d RFS and OS of 152 HGSC patients who did not receive neoadjuvant chemotherapy, upon stratification based on median CALR expression and stage. e RFS and OS of 111 HGSC patients stage III who did not receive neoadjuvant chemotherapy, upon stratification based on median CALR expression (f) OS of 302 HGSC patients from the TCGA public database upon stratification based on median CALR expression. Survival curves were estimated by the Kaplan-Meier method, and difference between groups were evaluated using log-rank test. Number of patients at risk are reported
Fig. 1 Prognostic impact of CALR expression in the primary TME of HGSC patients. a Representative images of CALR immunostaining in CALRLo and CALRHi patients. Scale bar = 100 μm. b CALR expression levels among different pathological disease stages. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. RFS (c) and OS (d) of 152 HGSC patients who did not receive neoadjuvant chemotherapy, upon stratification based on median CALR expression. d RFS and OS of 152 HGSC patients who did not receive neoadjuvant chemotherapy, upon stratification based on median CALR expression and stage. e RFS and OS of 111 HGSC patients stage III who did not receive neoadjuvant chemotherapy, upon stratification based on median CALR expression (f) OS of 302 HGSC patients from the TCGA public database upon stratification based on median CALR expression. Survival curves were estimated by the Kaplan-Meier method, and difference between groups were evaluated using log-rank test. Number of patients at risk are reportedCC BY · PubMed Central
Fig. 2 CALR exposure correlate with robust intracellular stress response in the TME. Correlation between CALR mRNA levels and DDIT3, HSPA5, or HSP90B1 mRNA levels in PT (a) and MT (b) samples of 24 patients with HGSC from study group 1 and in (c) 302 patients with HGSC from TCGA public database. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum
Fig. 2 CALR exposure correlate with robust intracellular stress response in the TME. Correlation between CALR mRNA levels and DDIT3, HSPA5, or HSP90B1 mRNA levels in PT (a) and MT (b) samples of 24 patients with HGSC from study group 1 and in (c) 302 patients with HGSC from TCGA public database. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximumCC BY · PubMed Central
Fig. 3 Transcriptional signatures of the tumor microenvironment of CALRHi versus CALRLo HGSCs. a Hierarchical clustering of significantly upregulated and downregulated genes in 77 CALRHi versus 77 CALRLo HGSC patients from the TCGA public database (302 patients were divided into 4 groups using quartile stratification, only lower (no = 77) and upper (no = 77) quartile is presented). b Relative expression levels of genes linked to T cells activation, TH1 polarization, T cell migration, cytotoxicity, antigen processing, activated DCs (aDCs), B cells and NK cells in 77 CALRHi versus 77 CALRLo TCGA HGSCs (302 patients were divided into 4 groups using quartile stratification, only lower (no = 77) and upper (no = 77) quartile is presented). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. c Relative abundance of CD8+ T cells and cytotoxic effector functions across 77 CALRHi and 77 CALRLo TCGA HGSCs (302 patients were divided into 4 groups using quartile stratification, only lower (no = 77) and upper (no = 77) quartile is presented). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum
Fig. 3 Transcriptional signatures of the tumor microenvironment of CALRHi versus CALRLo HGSCs. a Hierarchical clustering of significantly upregulated and downregulated genes in 77 CALRHi versus 77 CALRLo HGSC patients from the TCGA public database (302 patients were divided into 4 groups using quartile stratification, only lower (no = 77) and upper (no = 77) quartile is presented). b Relative expression levels of genes linked to T cells activation, TH1 polarization, T cell migration, cytotoxicity, antigen processing, activated DCs (aDCs), B cells and NK cells in 77 CALRHi versus 77 CALRLo TCGA HGSCs (302 patients were divided into 4 groups using quartile stratification, only lower (no = 77) and upper (no = 77) quartile is presented). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. c Relative abundance of CD8+ T cells and cytotoxic effector functions across 77 CALRHi and 77 CALRLo TCGA HGSCs (302 patients were divided into 4 groups using quartile stratification, only lower (no = 77) and upper (no = 77) quartile is presented). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximumCC BY · PubMed Central
Fig. 4 CALR expression positively correlate with the frequency of mature DC-LAMP+ DCs and CD20+ B cells. a Representative images of DC-LAMP and CD20 immunostaining. Scale bar = 50 μm. b Density of DC-LAMP+ cells and CD20+ B cells in TME of CALRLo versus CALRHi HGSCs (n = 82). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. OS of HGSC patients (study group 1) who did not receive neoadjuvant chemotherapy, upon stratification based on median expression of CALR and density of DC-LAMP+ cells (c) or CD20+ B cells (d)
Fig. 4 CALR expression positively correlate with the frequency of mature DC-LAMP+ DCs and CD20+ B cells. a Representative images of DC-LAMP and CD20 immunostaining. Scale bar = 50 μm. b Density of DC-LAMP+ cells and CD20+ B cells in TME of CALRLo versus CALRHi HGSCs (n = 82). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. OS of HGSC patients (study group 1) who did not receive neoadjuvant chemotherapy, upon stratification based on median expression of CALR and density of DC-LAMP+ cells (c) or CD20+ B cells (d)CC BY · PubMed Central
Fig. 5 Impact of CALR on the frequency and cytotoxicity of CD8 T cells in HGSC and immune contexture of HGSC. Representative images of CD8 (a) and Nkp46 (b) immunostaining. Scale bar = 50 μm. Density of CD8+ (c) and NK (d) cells in TME of CALRLo versus CALRHi HGSCs (n = 82). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. e Percentage of IFN-γ+ and IFN-γ+ /GZMB+ cells among CD8+ T cells from the HGSC of 17 CALRLo and 18 CALRHi patients after non-specific stimulation. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. f Expression levels of IFNG, GZMB, GZMA, GZMM, GZMH, GNLY in CALRHi patients from the TCGA database as compared to their CALRLo counterparts. (302 patients were divided into 4 groups using quartile stratification, only lower (no = 77) and upper (no = 77) quartile is presented). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. g OS of HGSC patients (study group 1) who did not receive neoadjuvant chemotherapy, upon stratification based on median expression of CALR and density of CD8+ cells. Survival curves were estimated by the Kaplan-Meier method, and difference between groups were evaluated using log-rank test. Number of patients at risk are reported. h Clustering of HGSC patients from study group 1 based on median stratification of CALR expression and median densities of DC-LAMP+, CD8+ and CD20+ cells as determined by immunohistochemistry. i RFS and OS of HGSC patients from study group 1 who did not receive neoadjuvant chemotherapy, upon stratification based on median expression of CALR and median density of immune infiltrate as indicated by clustering heatmap. Survival curves were estimated by the Kaplan-Meier method, and differences between groups were evaluated using log-rank test. Number of patients at risk are reported
Fig. 5 Impact of CALR on the frequency and cytotoxicity of CD8 T cells in HGSC and immune contexture of HGSC. Representative images of CD8 (a) and Nkp46 (b) immunostaining. Scale bar = 50 μm. Density of CD8+ (c) and NK (d) cells in TME of CALRLo versus CALRHi HGSCs (n = 82). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. e Percentage of IFN-γ+ and IFN-γ+ /GZMB+ cells among CD8+ T cells from the HGSC of 17 CALRLo and 18 CALRHi patients after non-specific stimulation. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. f Expression levels of IFNG, GZMB, GZMA, GZMM, GZMH, GNLY in CALRHi patients from the TCGA database as compared to their CALRLo counterparts. (302 patients were divided into 4 groups using quartile stratification, only lower (no = 77) and upper (no = 77) quartile is presented). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. g OS of HGSC patients (study group 1) who did not receive neoadjuvant chemotherapy, upon stratification based on median expression of CALR and density of CD8+ cells. Survival curves were estimated by the Kaplan-Meier method, and difference between groups were evaluated using log-rank test. Number of patients at risk are reported. h Clustering of HGSC patients from study group 1 based on median stratification of CALR expression and median densities of DC-LAMP+, CD8+ and CD20+ cells as determined by immunohistochemistry. i RFS and OS of HGSC patients from study group 1 who did not receive neoadjuvant chemotherapy, upon stratification based on median expression of CALR and median density of immune infiltrate as indicated by clustering heatmap. Survival curves were estimated by the Kaplan-Meier method, and differences between groups were evaluated using log-rank test. Number of patients at risk are reportedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 85

Metadata

Authors
Kasikova, L., Hensler, M., Truxova, I., Skapa, P., Laco, J., Belicova, L., Praznovec, I., Vosahlikova, S., Halaska, M. J., Brtnicky, T., Rob, L., Presl, J., Kostun, J., Cremer, I., Ryska, A., Kroemer, G., Galluzzi, L., Spisek, R., & Fucikova, J.
Affiliations
  • Sotio (Czechia) (CZ)
  • Inserm (FR)
  • Karolinska University Hospital (SE)
  • Yale University (US)
  • Charles University (CZ)
Corresponding author
Fucikova, Jitka
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-11-20
Volume
7
Issue
1
Pages
312-312
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2990968959
Cited by
79
References
44
Citations by year
2026: 10 · 2025: 5 · 2024: 13 · 2023: 8 · 2022: 14 · 2021: 15 · 2020: 14
FWCI
10.28
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Defense (#BC180476P1)
  • Weill Cornell Medical College
  • European Regional Development Fund (EF16_013/0001674)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
calreticulin, high-grade serous carcinoma, ovarian carcinoma, adjuvant effect, endoplasmic reticulum stress, tumor microenvironment, antitumor immunity, prognostic factors, metastatic ovarian cancer, innate immunity, adaptive immunity, cytotoxic T lymphocytes
MeSH terms
RNA-Seq, Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Ovarian Neoplasms, Prognosis, Calreticulin, Tumor Microenvironment, Endoplasmic Reticulum Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. https://app.cochat.ai/papers/10.1186/s40425-019-0781-z
The paper
Kasikova, L., Hensler, M., Truxova, I., Skapa, P., Laco, J., Belicova, L., Praznovec, I., Vosahlikova, S., Halaska, M. J., Brtnicky, T., Rob, L., Presl, J., Kostun, J., Cremer, I., Ryska, A., Kroemer, G., Galluzzi, L., Spisek, R., & Fucikova, J. (2019). Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0781-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.